Amid Novo Nordisk's Win for Ozempic's Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists' Rising Influence in GLP-1 RA Utilization
1. GLP-1 receptor agonist adoption by nephrologists has sharply increased. 2. Ozempic's FDA label expansion supports CKD treatment roles. 3. Treatment rates for GLP-1s in CKD nearly doubled from 2023 to 2024. 4. SGLT2 inhibitors remain essential despite competition from GLP-1s. 5. Safety concerns temper broader adoption of MRAs like Bayer's Kerendia.